Brexit could mean delays for cancer treatments and less safe medicinesBMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5685 (Published 07 December 2017) Cite this as: BMJ 2017;359:j5685
- Adrian O’Dowd
Patients could face delays in receiving lifesaving treatments and their medicines may be less safe if the UK does not secure a good post-Brexit deal and transitional arrangements, experts have warned MPs.
Speaking at an evidence session of the parliamentary health committee on 5 December for its inquiry into the potential effects of Brexit on the supply chain of medicines, medical devices, and other medical products, witnesses warned of the dangers of disrupting drug supply chains between the UK and the EU after Brexit.
MPs asked witnesses what a realistic worst case scenario could be after Britain leaves the EU. Martin Sawer, executive director of the Healthcare Distribution Association, which represents the UK’s major drug …